Mirtazapine: Difference between revisions
Jump to navigation
Jump to search
imported>David Finn No edit summary |
Pat Palmer (talk | contribs) m (Text replacement - "United States" to "United States of America") |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Mirtazapine''' is a [[second-generation antidepressant]] agent. | '''Mirtazapine''' is a [[second-generation antidepressant]] agent. Mirtazapine is also classified as a [[tricyclic antidepressant]] by the [[National Library of Medicine]] in the [[United States of America]].<ref>{{MeSH|Mirtazapine }}</ref> | ||
==History== | |||
Remeron brand of mirtazapine was approved for Organon USA by the [[Food and Drug Administration]] in the [[United States of America]] with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 1996.<ref>{{FDA-Drug_Details|020415}}</ref> A generic version with a AB [[Food and Drug Administration/Catalogs/Therapeutic Equivalence Code|Therapeutic Equivalence Code]] was approved for Glenmark Generics with a [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2004.<ref>{{FDA-Drug_Details|076119}}</ref> | |||
==Effectiveness== | |||
"The clinical response of our patients underscores the usefulness of mirtazapine in the treatment of the comorbid symptoms of weight loss, insomnia, and anxiety". <ref name="pmid11573849">{{cite journal| author=Raji MA, Brady SR| title=Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. | journal=Ann Pharmacother | year= 2001 | volume= 35 | issue= 9 | pages= 1024-7 | pmid=11573849 | doi= | pmc= | url= }} </ref> | "The clinical response of our patients underscores the usefulness of mirtazapine in the treatment of the comorbid symptoms of weight loss, insomnia, and anxiety". <ref name="pmid11573849">{{cite journal| author=Raji MA, Brady SR| title=Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. | journal=Ann Pharmacother | year= 2001 | volume= 35 | issue= 9 | pages= 1024-7 | pmid=11573849 | doi= | pmc= | url= }} </ref> | ||
[[Amitriptyline]], mirtazapine, and [[paroxetine]] may case more weight gain than other [[ | ==Pharmacology== | ||
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA).<ref name="pmid22161405">{{cite journal| author=Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R et al.| title=Mirtazapine versus other antidepressive agents for depression. | journal=Cochrane Database Syst Rev | year= 2011 | volume= 12 | issue= | pages= CD006528 | pmid=22161405 | doi=10.1002/14651858.CD006528.pub2 | pmc= | url= }} </ref> | |||
===Administration=== | |||
===Distribution=== | |||
===Metabolism=== | |||
===Excretion=== | |||
===Toxicity=== | |||
[[Drug toxicity]] is similar to [[tricyclic antidepressant]]s. [[Amitriptyline]], mirtazapine, and [[paroxetine]] may case more weight gain than other [[antidepressant]]s according to a [[meta-analysis]].<ref name="pmid21062615">{{cite journal| author=Serretti A, Mandelli L| title=Antidepressants and body weight: a comprehensive review and meta-analysis. | journal=J Clin Psychiatry | year= 2010 | volume= 71 | issue= 10 | pages= 1259-72 | pmid=21062615 | doi=10.4088/JCP.09r05346blu | pmc= | url= }} </ref> | |||
Compared to other [[antidepressant]]s, a second [[meta-analysis]] found that mirtazapine was "more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction."<ref name="pmid22161405">{{cite journal| author=Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R et al.| title=Mirtazapine versus other antidepressive agents for depression. | journal=Cochrane Database Syst Rev | year= 2011 | volume= 12 | issue= | pages= CD006528 | pmid=22161405 | doi=10.1002/14651858.CD006528.pub2 | pmc= | url= }} </ref> | |||
Mirtazapine can cause elevated [[liver function test]]s and [[neutropenia]]<ref name="pmid8930008">{{cite journal| author=Montgomery SA| title=Safety of mirtazapine: a review. | journal=Int Clin Psychopharmacol | year= 1995 | volume= 10 Suppl 4 | issue= | pages= 37-45 | pmid=8930008 | doi= | pmc= | url= }} </ref> | |||
==External links== | |||
{{CZMed}} | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 13:08, 2 February 2023
Mirtazapine is a second-generation antidepressant agent. Mirtazapine is also classified as a tricyclic antidepressant by the National Library of Medicine in the United States of America.[1]
History
Remeron brand of mirtazapine was approved for Organon USA by the Food and Drug Administration in the United States of America with a New Drug Application (NDA) in 1996.[2] A generic version with a AB Therapeutic Equivalence Code was approved for Glenmark Generics with a Abbreviated New Drug Application (ANDA) in 2004.[3]
Effectiveness
"The clinical response of our patients underscores the usefulness of mirtazapine in the treatment of the comorbid symptoms of weight loss, insomnia, and anxiety". [4]
Pharmacology
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA).[5]
Administration
Distribution
Metabolism
Excretion
Toxicity
Drug toxicity is similar to tricyclic antidepressants. Amitriptyline, mirtazapine, and paroxetine may case more weight gain than other antidepressants according to a meta-analysis.[6]
Compared to other antidepressants, a second meta-analysis found that mirtazapine was "more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction."[5]
Mirtazapine can cause elevated liver function tests and neutropenia[7]
External links
The most up-to-date information about Mirtazapine and other drugs can be found at the following sites.
- Mirtazapine - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Mirtazapine - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Mirtazapine - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Mirtazapine (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous. Drugs@FDA for FDA Application No. 020415. U S Food and Drug Administration
- ↑ Anonymous. Drugs@FDA for FDA Application No. 076119. U S Food and Drug Administration
- ↑ Raji MA, Brady SR (2001). "Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.". Ann Pharmacother 35 (9): 1024-7. PMID 11573849. [e]
- ↑ 5.0 5.1 Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R et al. (2011). "Mirtazapine versus other antidepressive agents for depression.". Cochrane Database Syst Rev 12: CD006528. DOI:10.1002/14651858.CD006528.pub2. PMID 22161405. Research Blogging.
- ↑ Serretti A, Mandelli L (2010). "Antidepressants and body weight: a comprehensive review and meta-analysis.". J Clin Psychiatry 71 (10): 1259-72. DOI:10.4088/JCP.09r05346blu. PMID 21062615. Research Blogging.
- ↑ Montgomery SA (1995). "Safety of mirtazapine: a review.". Int Clin Psychopharmacol 10 Suppl 4: 37-45. PMID 8930008. [e]